IP Library › Patent Application 14604543

Patent Application

App. No. 14/604,543

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 14/604,543

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Tip-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Tip-p8 expression.

Claims (188)

1 . A compound of Formula VIII

wherein

R 22 is a linker moiety selected from the group consisting of oxyacetamide, urea, carbamate, thiourea, sulfonamide, amine, and amide;

R 23 is selected from the group consisting of H, an aliphatic group of up to 25 carbons, and an aryl group of up to 10 carbons selected from the group consisting of substituted phenyl, phenalkyl, substituted phenalkyl, naphthyl, substituted naphthyl, and pyridyl;

R 24 is selected from the group consisting of H, OH, and an aliphatic group containing up to 25 carbon atoms; and

R 25 is H.

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . A composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient or diluent.

6 . (canceled)

7 . (canceled)

8 . A method for decreasing the viability of a Trp-p8 expressing cell, said method comprising the step of contacting said cell with a small-molecule Trp-p8 modulator in a concentration and for a time required to decrease the viability of said cell.

9 . The method of claim 8 wherein said small-molecule Trp-p8 modulator is selected from the group consisting of a compound of Formula I

wherein

R 1 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 2 is H;

R 3 is selected from the group consisting of ═O, OH, acetate, lactate, carboxamide, butanamide, sulphanamide, and propanetriol; and

R 4 is selected from the group consisting of CH 3 —CH—CH 3 (isopropyl), isopropane-2-ol, and CH 3 —C═CH 2 (isopropenyl),

a compound of Formula II

wherein

R 5 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 6 is N;

R 7 is selected from the group consisting of O and N;

R 8 is selected from the group consisting of NH, O, and S; and

R 9 is NO 2 ,

a compound of Formula III

wherein

R 10 is selected from the group consisting of H and a C 1 -C 5 alkyl;

R 11 is selected from the group consisting of OH carboxamide butanamide propanetriol, and CONR′R″, wherein R′ is selected from the group consisting of H, CH 3 , C 2 H 5 , C 4 H 8 (cyclobutyl), and C 4 H 8 O, and wherein R″ is selected from the group consisting of C 2 —H 5 , CH 3 —CH—CH 3 (isopropyl), HOCH 2 C(CH 3 ) 2 , HOCH 2 CH 2 , C 4 H 9 (tertbutyl), and C 4 H 9 (secbutyl);

R 12 is selected from the group consisting of H and a C 1 -C 5 alkyl; and

R 13 is selected from the group consisting of H and a C 1 -C 5 alkyl,

a compound of Formula IV

wherein

R 14 is selected from the group consisting of H, an aliphatic group of up to 25 carbons, and an aryl group of up to 10 carbons selected from the group consisting of substituted phenyl, phenalkyl, substituted phenalkyl, naphthyl, substituted naphthyl, and pyridyl; and

R 15 is selected from the group consisting of H, OH, and an aliphatic group containing up to 25 carbon atoms,

a compound of Formula V

wherein

R 16 is a C 2 -C 6 alkylene group having at least one, but not more than three, hydroxyl groups; and

R 17 and R 18 , independently of one another, are selected from the group consisting of C 1 -C 10 -alkyl, C 5 -C 7 -cycloalkyl, and C 6 -C 12 -aryl, wherein the total of the C atoms of R 17 and R 18 is not less than 3, or R 17 and R 18 together represent an alkylene group that, together with the carbon atom that carries the groups R 17 and R 18 , forms a 5-7-membered ring,

a compound of Formula VI,

a compound of Formula VII

wherein

R 17 is selected from the group consisting of 2-pyridyl, 2-nitro-4-trifluoromethylphenyl, 2-nitro-4-chlorophenyl, 2-methoxyphenyl, 2-chlorophenyl, phenyl, 2-methyl-quinolin-3-yl, 4-methoxyphenyl, 4-fluorophenyl, 3-azepanl-yl-5-(4-trifluoromethoxyl)phenylamino[1,3,5]triazyl, cyclohexyl, diphenylmethyl, 2-phenylethyl, 4-hydroxy-cyclohexyl, cycloheptyl, cyclopentyl, C-benzo[1,3]dioxol-5-yl-methyl, 2-pyridyl, and 4-chlorobenzyl;

R 18 is selected from the group consisting of 1-benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 3-benzylamino-2-nitrophenyl, 5-nitro-quinolin-8-yl, 1-yl-3-(2-isopropyl-5-methylcyclohexyloxy)-propan-2-ol 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, benzyl-2-methylquinazolin-4-yl, 3-methyl-5-morpholin-4-yl-2-nitro-phenyl, 2-nitro-5-piperazin-1-yl-ethanol 1-yl-3-(2-isopropyl-5-methyl-cyclohexyloxy)-propan-2-ol, 4-(2,5-dimethyl-pyrrol-1-yl)-2-nitro-phenyl, 2-nitro-3-trifluoromethanesulfonyl-phenyl, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 2-(2-Fluoro-phenoxymethyl)-2-cyano oxazolyl, adamantly, 5-(benzo[1,3]dioxol-5-ylamino)-10b,10c-dihydro-anthra[1,9-cd]isoxazol-6-one-yl, 2-methylthiazolo[3,2-b][1,2,4]triazol-6-01 4-methylphenyl methyl, 3-benzyl-3H-quinazolin-4-one-2-yl, cyclopentyl, tetrahydronapthyl, cyclooctyl, cyclohexyl, C-[3-(4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-methyl, C-(2-benzyl-5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-methyl, and 1-yl-3-(2-isopropyl-5-methyl cyclohexyloxy)-propan-2-ol;

R 19 and R 20 are each independently selected from the group consisting of H and O; and

R 21 is selected from the group consisting of 4-methylphenyl, 2-chloro-4-fluorophenyl, and 4-chlorophenyl, and

a compound of Formula VIII

wherein

R 22 is a linker moiety selected from the group consisting of oxyacetamide, urea, carbamate, thiourea, sulfonamide, amine, and amide;

R 23 is selected from the group consisting of H, tetrahydro isoquinolinyl, tetrahydro quinolinyl, 3-methyl indolinyl, indolinyl, 2-(N-methyl,N-phenylethyl)amino ethyl, 3-methyl indolinyl, 1-phenyl ethyl, 2-chloro benzyl, 2-methoxybenzyl, 2-methoxyphenyl, 2-cyclohex-1-enyl ethyl, (1-phenyl-cyclophentyl)-methyl, 2-(tetrahydroquinolinyl)-ethyl, 1-propyl-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine, cycloheptyl, 3-cyclohexylsulfanylpropyl, 2-cyclohex-1-enyl ethyl, 2-(N-isopropyl,N-phenylethyl)amino ethyl, 1-methyl-1,2,3,4-tetrhydro-pyrrolo[1,2-a]pyrazine, 2-cyclopentylethyl, 2-phenylcyclopropyl, 1-phenoxyethyl, 4-butyloxyphenyl, (2-nitrophenoxy)methyl, 4,7,7-trimethyl-2-oxa-bicyclo[2.2.1]heptan-3-one, C-(1-phenyl-5-propyl-IH-pyrazol-4-yl)-methyl, benzyl, 2-chlorobenzyl, 1-[3-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-methoxy-phenyl]-2,3,4,9-tetrahydro-1H-b-carboline, C-[3-(4-butoxy-phenyl)-1H-pyrazol-4-yl]-methyl, 4-(azepane-1-sulfonyl)-phenyl, and 5-(7-chloro-quinolin-4-ylsulfanyl)-[1,3,4]thiadiazol-2-yl;

R 24 is selected from the group consisting of H, tetrahydro isoquinolinyl, tetrahydro quinolinyl, 3-methyl indolinyl, indolinyl, 3-methyl indolinyl, 1-propyl-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine, 1-methyl-1,2,3,4-tetrhydro-pyrrolo[1,2-a]pyrazine, and 1-[3-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-methoxy-phenyl]-2,3,4,9tetrahydro-1H-b-carboline; and

R 25 is H.

10 . The method of claim 9 wherein said small-molecule Trp-p8 modulator is a compound of Formula I

wherein

R 1 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 2 is H;

R 3 is selected from the group consisting of O, OH, acetate, lactate, carboxamide, butanamide, sulphanamide, and propanetriol; and

R 4 is selected from the group consisting of CH 3 —CH—CH 3 (isopropyl), isopropane-2-ol, and CH 3 —C—CH 2 (isopropenyl).

11 . The method of claim 9 wherein said small-molecule Trp-p8 agonist is a compound of Formula II

wherein

R 5 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 6 is N;

R 7 is selected from the group consisting of O and N;

R 8 is selected from the group consisting of NH, O, and S; and

R 9 is NO 2 .

12 . The method of claim 9 wherein said small-molecule Trp-p8 modulator is a compound of Formula III

wherein

R 10 is selected from the group consisting of H and a C 1 -C 5 alkyl;

R 11 is selected from the group consisting of OH, carboxamide, butanamide, propanetriol, and CONR′R″, wherein R′ is selected from the group consisting of H, CH 3 , C 2 H 5 , C 4 H 8 (cyclobutyl), and C 4 H 8 O, and wherein R″ is selected from the group consisting of C 2 —H 5 , CH 3 —CH—CH 3 (isopropyl), HOCH 2 C(CH 3 ) 2 , HOCH 2 CH 2 , C 4 H 9 (tertbutyl), and C 4 H 9 (secbutyl);

R 12 is selected from the group consisting of H and a C 1 -C 5 alkyl; and

R 13 is selected from the group consisting of H and a C 1 -C 5 alkyl.

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . The method of claim 9 wherein said small-molecule Trp-p8 modulator is a compound of Formula V

wherein

R 16 is a C 2 -C 6 alkylene group having at least one, but not more than three, hydroxyl groups; and

19 . (canceled)

20 . The method of claim 9 wherein said small-molecule Trp-p8 modulator is a compound of Formula VII

wherein

R 18 is selected from the group consisting of 1-benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 3-benzylamino-2-nitrophenyl, 5-nitro-quinolin-8-yl, 1-yl-3-(2-isopropyl-5-methylcyclohexyloxy)-propan-2-ol, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, benzyl-2-methylquinazolin-4-yl, 3-methyl-5-morpholin-4-yl-2-nitro-phenyl, 2-nitro-5-piperazin-1-yl-ethanol, 1-yl-3-(2-isopropyl-5-methyl-cyclohexyloxy)-propan-2-ol, 4-(2,5-dimethyl-pyrrol-1-yl)-2-nitro-phenyl, 2-nitro-3-trifluoromethanesulfonyl-phenyl, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 2-(2-Fluoro-phenoxymethyl)-2-cyano oxazolyl, adamantly, 5-(benzo[1,3]dioxol-5-ylamino)-10b,10c-dihydro-anthra[1,9-cd]isoxazol-6-one-yl, 2-methylthiazolo[3,2-b][1,2,4]triazol-6-01 4-methylphenyl methyl, 3-benzyl-3H-quinazolin-4-one-2-yl, cyclopentyl, tetrahydronapthyl, cyclooctyl, cyclohexyl, C-[3-(4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-methyl, C-(2-benzyl-5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-methyl, and 1-yl-3-(2-isopropyl-5-methyl cyclohexyloxy)-propan-2-ol;

R 19 and R 29 are each independently selected from the group consisting of H and O; and

R 21 is selected from the group consisting of 4-methylphenyl, 2-chloro-4-fluorophenyl, and 4-chlorophenyl.

21 . The method of claim 9 wherein said small-molecule Trp-p8 modulator is a compound of Formula VIII

wherein

R 22 is a linker moiety selected from the group consisting of oxyacetamide, urea, carbamate, thiourea, sulfonamide, amine, and amide;

R 25 is H.

22 . A method for inducing apoptosis and/or necrosis in a cell expressing Trp-p8, said method comprising the step of administering to said cell a small-molecule Trp-p8 modulator selected from the group consisting of a compound of Formula I

wherein

R 1 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 2 is H;

R 3 is selected from the group consisting of ═O, OH, acetate, lactate, carboxamide, butanamide, sulphanamide, and propanetriol; and

R 4 is selected from the group consisting of CH 3 —CH—CH 3 (isopropyl), isopropane-2-ol, and CH 3 —C═CH 2 (isopropenyl),

a compound of Formula II

wherein

R 5 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 7 (isopropenyl);

R 6 is N;

R 7 is selected from the group consisting of O and N;

R 8 is selected from the group consisting of NH, O, and S; and

R 9 is NO 2 ,

a compound of Formula III

wherein

R 10 is selected from the group consisting of H and a C 1 -C 5 alkyl;

R 11 is selected from the group consisting of OH, carboxamide, butanamide, propanetriol, and CONR′R″, wherein R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 4 H 8 (cyclobutyl), and C 4 H 8 O, and wherein R″ is selected from the group consisting of C 2 —H 5 , CH 3 —CH—CH 3 (isopropyl), HOCH 2 C(CH 3 ) 2 , HOCH 2 CH 2 , C 4 H 9 (tertbutyl), and C 4 H 9 (secbutyl);

R 12 is selected from the group consisting of H and a C 1 -C 5 alkyl; and

R 13 is selected from the group consisting of H and a C 1 -C 5 alkyl,

a compound of Formula IV

wherein

R 15 is selected from the group consisting of H, OH, and an aliphatic group containing up to 25 carbon atoms,

a compound of Formula V

wherein

R 16 is a C 2 -C 6 alkylene group having at least one, but not more than three, hydroxyl groups; and

a compound of Formula VI,

a compound of Formula VII

wherein

R 18 is selected from the group consisting of 1-benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 3-benzylamino-2-nitrophenyl, 5-nitro-quinolin-8-yl, 1-yl-3-(2-isopropyl-5-methylcyclohexyloxy)-propan-2-ol, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, benzyl-2-methylquinazolin-4-yl, 3-methyl-5-morpholin-4-yl-2-nitro-phenyl, 2-nitro-5-piperazin-1-yl-ethanol, 1-yl-3-(2-isopropyl-5-methyl-cyclohexyloxy)-propan-2-ol, 4-(2,5-dimethyl-pyrrol-1-yl)-2-nitro-phenyl, 2-nitro-3-trifluoromethanesulfonyl-phenyl, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 2-(2-Fluoro-phenoxymethyl)-2-cyano oxazolyl, adamantly, 5-(benzo[1,3]dioxol-5-ylamino)-10b,10c-dihydro-anthra[1,9-cd]isoxazol-6-one-yl, 2-methylthiazolo[3,2-b][1,2,4]triazol-6-01 4-methylphenyl methyl, 3-benzyl-3H-quinazolin-4-one-2-yl, cyclopentyl, tetrahydronapthyl, cyclooctyl, cyclohexyl, C-[3-(4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-methyl, C-(2-benzyl-5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-methyl, and 1-yl-3-(2-isopropyl-5-methyl cyclohexyloxy)-propan-2-ol;

R 19 and R 20 are each independently selected from the group consisting of H and O; and

R 21 is selected from the group consisting of 4-methylphenyl, 2-chloro-4-fluorophenyl, and 4-chlorophenyl, and

a compound of Formula VIII

wherein

R 22 is a linker moiety selected from the group consisting of oxyacetamide, urea, carbamate, thiourea, sulfonamide, amine, and amide;

R 25 is H.

23 . A method for treating a disease associated with Trp-p8 expression, said method comprising the steps of administering to a mammal an efficacious amount of a composition comprising a compound of Formula I

wherein

R 1 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH 2 (isopropenyl);

R 2 is H;

R 3 is selected from the group consisting of ═O, OH, acetate, lactate, carboxamide, butanamide, sulphanamide, and propanetriol; and

R 4 is selected from the group consisting of CH 3 —CH—CH 3 (isopropyl), isopropane-2-ol, and CH 3 —C═CH 2 (isopropenyl),

a compound of Formula II

wherein

R 5 is selected from the group consisting of H, OH, CH 3 , CH 3 —CH—CH 3 (isopropyl), and CH 3 —C═CH, (isopropenyl);

R 6 is N;

R 7 is selected from the group consisting of O and N;

R 8 is selected from the group consisting of NH, O, and S; and

R 9 is NO 2 ,

a compound of Formula III

wherein

R 10 is selected from the group consisting of H and a C 1 -C 5 alkyl;

R 12 is selected from the group consisting of H and a C 1 -C 5 alkyl; and

R 13 is selected from the group consisting of H and a C 1 -C 5 alkyl,

a compound of Formula IV

wherein

R 15 is selected from the group consisting of H, OH, and an aliphatic group containing up to 25 carbon atoms,

a compound of Formula V

wherein

R 16 is a C 2 -C 6 alkylene group having at least one, but not more than three, hydroxyl groups; and

a compound of Formula VI,

a compound of Formula VII

wherein

R 17 is selected from the group consisting of 2-pyridyl, 2-nitro-4-trifluoromethylphenyl, 2-nitro-4-chlorophenyl, 2-methoxyphenyl, 2-chlorophenyl, phenyl, 2-methyl-quinolin-3-yl, 4-methoxyphenyl, 4-fluorophenyl, 3-azepanl-yl-5-(4-trifluoromethoxy)phenylamino[1,3,5]triazyl, cyclohexyl, diphenylmethyl, 2-phenylethyl, 4-hydroxy-cyclohexyl, cycloheptyl, cyclopentyl, C-benzo[1,3]dioxol-5-yl-methyl, 2-pyridyl, and 4-chlorobenzyl;

R 18 is selected from the group consisting of 1-benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 3-benzylamino-2-nitrophenyl, 5-nitro-quinolin-8-yl, 1-yl-3-(2-isopropyl-5-methylcyclohexyloxy)-propan-2-ol 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-1 benz 1-2-methylquinazolin-4-yl, 3-methyl-5-morpholin-4-yl-2-nitro-phenyl, 2-nitro-5-piperazin-1-yl-ethanol, 1-yl-3-(2-isopropyl-5-methyl-cyclohexyloxy)-propan-2-ol, 4-(2,5-dimethyl-pyrrol-1-yl)-2-nitro-phenyl, 2-nitro-3-trifluoromethanesulfonyl-phenyl, 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl, 2-(2-Fluoro-phenoxymethyl)-2-cyano oxazolyl, adamantly, 5-(benzo[1,3]dioxol-5-ylamino)-10b,10c-dihydro-anthra[1,9-cd]isoxazol-6-one-yl, 2-methylthiazolo[3,2-b][1,2,4]triazol-6-01 4-methylphenyl methyl, 3-benzyl-3H-quinazolin-4-one-2-yl, cyclopentyl, tetrahydronapthyl, cyclooctyl, cyclohexyl, C-[3-(4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-methyl, C-(2-benzyl-5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-methyl, and 1-yl-3-(2-isopropyl-5-methyl cyclohexyloxy)-propan-2-ol;

R 19 and R 20 are each independently selected from the group consisting of H and O; and

R 21 is selected from the group consisting of 4-methylphenyl, 2-chloro-4-fluorophenyl, and 4-chlorophenyl, and

a compound of Formula VIII

wherein

R 22 is a linker moiety selected from the group consisting of oxyacetamide, urea, carbamate, thiourea, sulfonamide, amine, and amide;

R 23 is selected from the group consisting of H, tetrahydro isoquinolinyl, tetrahydro quinolinyl, 3-methyl indolinyl, indolinyl, 2-(N-methyl,N-phenylethyl)amino ethyl, 3-methyl indolinyl, 1-phenyl ethyl, 2-chloro benzyl, 2-methoxybenzyl, 2-methoxyphenyl, 2-cyclohex-1-enyl ethyl, (1-phenyl-cyclophentyl)-methyl, 2-(tetrahydroquinolinyl)-ethyl, 1-propyl-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine, cycloheptyl, 3-cyclohexylsulfanylpropyl, 2-cyclohex-1-enyl ethyl, 2-(N-isopropyl,N-phenylethyl)amino ethyl, 1-methyl-1,2,3,4-tetrhydro-pyrrolo[1,2-a]pyrazine, 2-cyclopentylethyl, 2-phenylcyclopropyl, 1-phenoxyethyl, 4-butyloxyphenyl, (2-nitrophenoxy)methyl, 4,7,7-trimethyl-2-oxa-bicyclo[2.2.1]heptan-3-one, C-(1-phenyl-5-propyl-IH-pyrazol-4-yl)-methyl, benzyl, 2-chlorobenzyl, 1-[3-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-methoxy-phenyl]-2,3,4,9-tetrahydro-1H-b-carboline C-[3-(4-butoxy-phenyl)-1H-pyrazol-4-yl]-methyl, 4-(azepane-1-sulfonyl)-phenyl, and 5-(7-chloro-quinolin-4-ylsulfanyl)-[1,3,4]thiadiazol-2-yl;

R 25 is H.

24 . (canceled)

25 . (canceled)

26 . (canceled)

27 . (canceled)

28 . (canceled)

29 . (canceled)

30 . (canceled)

31 . (canceled)

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . (canceled)

36 . A method for identifying a Trp-p8 agonist, said method comprising the step of contacting a Trp-p8 expressing cell and a non-Trp-p8 expressing cell with a candidate Trp-p8 agonist for a time and in an amount sufficient to decrease the viability of said Trp-p8 expressing cell but not said non-Trp-p8 expressing cell.

37 . A method for identifying a Trp-p8 antagonist, said method comprising the step of contacting a Trp-p8 expressing cell with a Trp-p8 agonist and with a candidate Trp-p8 antagonist for a time and in an amount sufficient for said agonist to decrease the viability of said T rp-p8 expressing cell, wherein a Trp-p8 antagonist is detected by an increase in the viability of said Trp-p8 expressing cell.

Assignments (7)

RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025

From: BARCLAYS BANK PLC, AS COLLATERAL AGENT

To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.

Reel/Frame 070778/0199 →

RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017

From: BARCLAYS BANK PLC

To: DENDREON PHARMACEUTICALS LLC

Reel/Frame 042905/0088 →

CHANGE OF NAME Recorded Apr 21, 2017

From: DENDREON PHARMACEUTICALS, INC.

To: DENDREON PHARMACEUTICALS LLC

Reel/Frame 042314/0088 →

CHANGE OF NAME Recorded Mar 14, 2017

From: DRONE ACQUISITION SUB INC.

To: DENDREON PHARMACEUTICALS, INC.

Reel/Frame 041994/0675 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2017

From: DENDREON CORPORATION

To: DRONE ACQUISITION SUB INC.

Reel/Frame 041554/0016 →

SECURITY INTEREST Recorded Jul 18, 2016

From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND

To: BARCLAYS BANK PLC

Reel/Frame 039380/0385 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015

From: NATARAJAN, SATEESH; MORENO, OFIR; GRADDIS, THOMAS J.; DUNCAN, DAVID F.; LAUS, REINER; CHEN, FENG

To: DENDREON CORPORATION

Reel/Frame 035272/0807 →